ArticleScientific reports2026

Real-world use of rivaroxaban for primary thromboprophylaxis and cardiac thrombosis treatment in congenital and acquired heart disease: a prospective cohort study.

Neil Derridj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.